Block of neural Kv1.1 potassium channels for neuroinflammatory disease therapy

Annals of Neurology

Volumn 60, Issue 5, 2006, Pages 586-596

  Beraud, Evelyne ^a,c   Viola, Angèle ^b   Regaya, Imed ^a,b   Confort Gouny, Sylviane ^b   Siaud, Philippe ^c   Ibarrola, Danielle ^b   Le Fur, Yann ^b   Barbaria, Jocelyne ^a   Pellissier, Jean François ^a   Sabatier, Jean Marc ^a,b   Medina, Igor ^c   Cozzone, Patrick J ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b CNRS   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALANINE; BETA ADENOSINE TRIPHOSPHATE; CREATINE PHOSPHATE; PEPTIDE BGK F6A; PEPTIDE FRAGMENT; PHENYLALANINE; PHOSPHATE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.1; VOLTAGE GATED POTASSIUM CHANNEL;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN DAMAGE; CELL VOLUME; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE RELEASE; DIFFUSION COEFFICIENT; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; ENERGY METABOLISM; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LEWIS RAT; LYMPHOCYTE PROLIFERATION; MULTIPLE SCLEROSIS; NERVE CONDUCTION; NERVE FIBER; NERVE INJURY; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; RAT; REGULATORY MECHANISM; REMYELINIZATION; STROKE; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE;

ANIMALS; ASTROCYTES; BLOOD-BRAIN BARRIER; BRAIN EDEMA; CELL PROLIFERATION; CNIDARIAN VENOMS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; MAGNETIC RESONANCE SPECTROSCOPY; RATS; RATS, INBRED LEW; SHAKER SUPERFAMILY OF POTASSIUM CHANNELS;

EID: 33845289461     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21007     Document Type: Article

References (66)

1. Veh RW, Lichtinghagen R, Sewing S, et al. Immunohistochemical localization of five members of the Kv1 channel subunits: contrasting subcellular locations and neuron-specific colocalizations in rat brain. Eur J Neurosci 1995;7:2189-2205.
2. Sheng M, Liao YJ, Jan YN, Jan LY. Presynaptic A-current based on heteromultimeric K+ channels detected in vivo. Nature 1993;365:72-75.
3. Wang H, Kunkel DD, Martin TM, et al. Heteromultimeric K+ channels in terminal and juxtaparanodal regions of neurons. Nature 1993;365:75-79.
4. Rasband MN, Shrager P. Ion channel sequestration in central nervous system axons. J Physiol 2000;525(pt 1):63-73.
5. Rasband M. Potassium channel organization of myelinated and demyelinated axons. In: Multiple Sclerosis as a neuronal disease. Ed: Stephen Waxman, London: Elsevier Academic Press, 2005:57-67.
6. Bostock H, Sears TA, Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol 1981;313:301-315.
7. Nashmi R, Fehlings MG. Mechanisms of axonal dysfunction after spinal cord injury: with an emphasis on the role of voltage-gated potassium channels. Brain Res Brain Res Rev 2001;38:165-191.
8. Judge SI, Bever CT Jr. Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 2006;111:224-259.
9. Frohman EM, Filippi M, Stuve O, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005;62:1345-1356.
10. Chandy GK, Wulff H, Beeton C, et al. K+ channels as targets for specific immunomodulation. Trends Pharmacol Sci 2004;25:280-289.
11. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343:938-952.
12. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005;128:2705-2712.
13. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006;60:12-21.
14. Alessandri-Haber N, Lecoq A, Gasparini S, et al. Mapping the functional anatomy of BgK on Kv1.1, Kv1.2, and Kv1.3. Clues to design analogs with enhanced selectivity. J Biol Chem 1999;274:35653-35661.
15. Gilquin B, Braud S, Eriksson MA, et al. A variable residue in the pore of Kv1 channels is critical for the high affinity of blockers from sea anemones and scorpions. J Biol Chem 2005;280:27093-27102.
16. Cadoux-Hudson TA, Kermode A, Rajagopalan B, et al. Biochemical changes within a multiple sclerosis plaque in vivo. J Neurol Neurosurg Psychiatry 1991;54:1004-1006.
17. Husted CA, Goodin DS, Hugg JW, et al. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 1994;36:157-165.
18. Beraud E, Balzano C, Zamora AJ, et al. Pathogenic and non-pathogenic T lymphocytes specific for the encephalitogenic epitope of myelin basic protein: functional characteristics and vaccination properties. J Neuroimmunol 1993;47:41-53.
19. Dauplais M, Lecoq A, Song J, et al. On the convergent evolution of animal toxins. Conservation of a diad of functional residues in potassium channel-blocking toxins with unrelated structures. J Biol Chem 1997;272:4302-4309.
20. Beeton C, Barbaria J, Giraud P, et al. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J Immunol 2001;166:936-944.
21. Beeton C, Wulff H, Barbaria J, et al. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci U S A 2001;98:13942-13947.
22. Paxinos L, Watson C. The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press, 1998.
23. Penet MF, Viola A, Confort-Gouny S, et al. Imaging experimental cerebral malaria in vivo: significant role of ischemic brain edema. J Neurosci 2005;25:7352-7358.
24. Karlik SJ, Munoz D, St Louis J, Strejan G. Correlation between MRI and clinico-pathological manifestations in Lewis rats protected from experimental allergic encephalomyelitis by acylated synthetic peptide of myelin basic protein. Magn Reson Imaging 1999;17:731-737.
25. Rudin M, Baumann D, Ekatodramis D, et al. MRI analysis of the changes in apparent water diffusion coefficient, T(2) relaxation time, and cerebral blood flow and volume in the temporal evolution of cerebral infarction following permanent middle cerebral artery occlusion in rats. Exp Neurol 2001;169:56-63.
26. DeCoursey TE, Chandy KG, Gupta S, Cahalan MD. Voltage-gated K+ channels in human T lymphocytes: a role in mitogenesis? Nature 1984;307:465-468.
27. Matteson DR, Deutsch C. K channels in T lymphocytes: a patch clamp study using monoclonal antibody adhesion. Nature 1984;307:468-471.
28. Sutro JB, Vayuvegula BS, Gupta S, Cahalan MD. Voltage-sensitive ion channels in human B lymphocytes. Adv Exp Med Biol 1989;254:113-122.
29. Gallin EK. Calcium- and voltage-activated potassium channels in human macrophages. Biophys J 1984;46:821-825.
30. Korotzer AR, Cotman CW. Voltage-gated currents expressed by rat microglia in culture. Glia 1992;6:81-88.
31. Fischer HG, Eder C. Voltage-gated K+ currents of mouse dendritic cells. FEBS Lett 1995;373:127-130.
32. Beeton C, Pennington MW, Wulff H, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005;67:1369-1381.
33. Grosse G, Draguhn A, Hohne L, et al. Expression of Kv1 potassium channels in mouse hippocampal primary cultures: development and activity-dependent regulation. J Neurosci 2000;20:1869-1882.
34. Wujek JR, Bjartmar C, Richer E, et al. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002;61:23-32.
35. Smith T, Groom A, Zhu B, Turski L. Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 2000;6:62-66.
36. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-437.
37. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003;126:2191-2202.
38. Bechtold DA, Yue X, Evans RM, et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 2005;128:18-28.
39. Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123(pt 1):171-184.
40. Kourrich S, Mourre C, Soumireu-Mourat B. Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats. Behav Brain Res 2001;120:35-46.
41. Akhtar S, McIntosh P, Bryan-Sisneros A, et al. A functional spliced-variant of beta 2 subunit of Kv1 channels in C6 glioma cells and reactive astrocytes from rat lesioned cerebellum. Biochemistry 1999;38:16984-16992.
42. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000;21:141-147.
43. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab 2003;23:137-149.
44. Wang D, Ayers MM, Catmull DV, et al. Astrocyte-associated axonal damage in pre-onset stages of experimental autoimmune encephalomyelitis. Glia 2005;51:235-240.
45. Turner B, Lin X, Calmon G, et al. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003;9:21-27.
46. Badaut J, Lasbennes F, Magistretti PJ, Regli L. Aquaporins in brain: distribution, physiology, and pathophysiology. J Cereb Blood Flow Metab 2002;22:367-378.
47. Amiry-Moghaddam M, Xue R, Hang FM, et al. Alpha-syntrophin deletion removes the perivascular but not endothelial pool of aquaporin-4 at the blood-brain barrier and delays the development of brain edema in an experimental model of acute hyponatremia. Faseb J 2004;18:542-544.
48. Aoki-Yoshino K, Uchihara T, Duyckaerts C, et al. Enhanced expression of aquaporin 4 in human brain with inflammatory diseases. Acta Neuropathol (Berl) 2005;110:281-288.
49. Speake T, Brown PD. Ion channels in epithelial cells of the choroid plexus isolared from the lateral ventricle of rat brain. Brain Res 2004;1005:60-66.
50. Werring DJ, Brassat D, Droogan AG, et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 2000;123(pt 8):1667-1676.
51. Iwasawa T, Matoba H, Ogi A, et al. Diffusion-weighted imaging of the human optic nerve: a new approach to evaluate optic neuritis in multiple sclerosis. Magn Reson Med 1997;38:484-491.
52. Heide AC, Richards TL, Alvord EC Jr, et al. Diffusion imaging of experimental allergic encephalomyelitis. Magn Reson Med 1993;29:478-484.
53. Richards TL, Alvord EC Jr, He Y, et al. Experimental allergic encephalomyelitis in non-human primates: diffusion imaging of acute and chronic brain lesions. Mult Scler 1995;1:109-117.
54. Sotak CH. Nuclear magnetic resonance (NMR) measurement of the apparent diffusion coefficient (ADC) of tissue water and its relationship to cell volume changes in pathological states. Neurochem Int 2004;45:569-582.
55. Kimelberg HK. Water homeostasis in the brain: basic concepts. Neuroscience 2004;129:851-860.
56. D'Amelio FE, Smith ME, Eng LF. Sequence of tissue responses in the early stages of experimental allergic encephalomyelitis (EAE): immunohistochemical, light microscopic, and ultrastructural observations in the spinal cord. Glia 1990;3:229-240.
57. Kimelberg HK. Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy. Glia 2005;50:389-397.
58. Zwingmann C, Leibfritz D. Ammonia toxicity under hyponatremic conditions in astrocytes: de novo synrnesis of amino acids for the osmoregulatory response. Neurochem Int 2005;47:39-50.
59. Shin CY, Choi JW, Ryu JR, et al. Immunostimulation of rat primary astrocytes decreases intracellular ATP level. Brain Res 2001;902:198-204.
60. Lian XY, Stringer JL. Energy failure in astrocytes increases the vulnerability of neurons to spreading depression. Eur J Neurosci 2004;19:2446-2454.
61. Fields RD, Stevens B. ATP: an extracellular signaling molecule between neurons and glia. Trends Neurosci 2000;23:625-633.
62. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006;59:478-489.
63. Heurteaux C, Laigle C, Blondeau N, et al. Alpha-Linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neuroscience 2006;137:241-251.
64. Neumann H, Misgeld T, Matsumuro K, Wekerle H. Neurotrophins inhibit major histocompatibility class II inducibility of microglia: involvement of the p75 neurotrophin receptor. Proc Nact Acad Sci U S A 1998;95:5779-5784.
65. Lo AC, Saab CY, Black JA, Waxman SG. Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. J Neurophysiol 2003;90:3566-3571.
66. Rus H, Pardo CA, Hu L, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci U S A 2005;102:11094-11099.